ASN's Mission

ASN leads the fight to prevent, treat, and cure kidney diseases throughout the world by educating health professionals and scientists, advancing research and innovation, communicating new knowledge, and advocating for the highest quality care for patients.

learn more

Contact ASN

1401 H St, NW, Ste 900, Washington, DC 20005

email@asn-online.org

202-640-4660

The Latest on Twitter

Kidney Week

Translational Session

Major Clinical Trials for Diabetic Kidney Disease: CREDENCE and SONAR

November 08, 2019 | 10:30 AM - 01:00 PM

Location: Hall D, Walter E. Washington Convention Center

Session Description

The CREDENCE clinical trial of an SGLT-2 inhibitor, canagliflozin, was stopped early for evidence of efficacy in patients with type 2 diabetes and diabetic kidney disease (DKD). SONAR is a clinical trial that tested the effect of an endothelin A receptor antagonist, atrasentan, for DKD with a unique enrichment design. This session presents the key elements of these landmark trials, which are expected to set a new course in motion for DKD.

Learning Objective(s)

  • Discuss the rationale and background for CREDENCE and SONAR
  • Describe new learnings from these pivotal clinical trials

Learning Pathway(s)

  • Diabetes and Metabolism

Moderators

  • Peter Rossing, MD
  • Katherine R. Tuttle, MD, FASN

Presentations

  • CREDENCE Background, Study Design, and Conduct
    10:30 AM - 11:00 AM
    Carol A. Pollock, MD, PhD
  • CREDENCE Primary Outcomes and Other Major Outcomes
    11:00 AM - 11:30 AM
    Meg J. Jardine, MBBS, PhD
  • SONAR Background, Study Design, and Conduct
    11:30 AM - 12:00 PM
    Hiddo Jan L Heerspink, PhD 
  • SONAR Primary Outcomes and Other Major Outcomes
    12:00 PM - 12:30 PM
    Dick de Zeeuw, MD, PhD
  • Panel and Audience Discussion
    12:30 PM - 12:50 PM